Wordt geladen...
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Russo |
| Gepubliceerd in: |
ABV-press
2021-09-01
|
| Reeks: | Opuholi Ženskoj Reproduktivnoj Sistemy |
| Onderwerpen: | |
| Online toegang: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|